Companies that are decreasing efficiency in utilisation of Shareholders funds ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

No other corporate actions details are available.